Stratvocate offers a wealth of information and easy-to-use tools for those involved in federal contracting.

Subject: High Performance Antigen Diagnostics
Solicitation Number: RRPV-HPAD
Notice Type: SRCSGT
NAICS: 541714
Set-Aside: No Set aside used
Notice Published: 06-17-26
Response Due: 07-17-26

Agency: Department of Health and Human Services
Office: OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Contact: ATI This email address is being protected from spambots. You need JavaScript enabled to view it.
Office Address: Washington, DC 20515
Place of Performance: Washington, DC


Click for official SAM (FBO) notice, additional information, and accompanying attachments

?High Performance Antigen Diagnostics? Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.